Apert Syndrome: FGFR2 Mutations and Molecular Diagnosis
*This article has been reviewed by a clinical geneticist at 3billion.
Apert syndrome is a severe autosomal dominant disorder defined by premature fusion of the cranial sutures together with symmetric syndactyly. It arises almost exclusively from recurrent gain-of-function variants in the FGFR2 gene, which encodes fibroblast growth factor receptor 2.
For clinicians, the diagnostic value lies in a tightly constrained genotype: two adjacent missense changes explain nearly all cases. That predictability makes molecular confirmation fast and recurrence-risk counseling relatively clear.
Frequently asked questions
How is Apert syndrome inherited?
Apert syndrome follows autosomal dominant inheritance. Most cases arise from de novo variants, often linked to advanced paternal age.
What are the main features of Apert syndrome?
The recognizable triad is bicoronal craniosynostosis, midface hypoplasia, and symmetric complex syndactyly of the hands and feet. Additional findings can include hydrocephalus, cleft palate, and variable cognitive outcomes.
How common is Apert syndrome?
Estimated prevalence is about 1 in 65,000 newborns, though reported figures range to 1 in 160,000. It accounts for roughly 4.5% of all craniosynostosis cases, placing it among the more common syndromic forms.
How is Apert syndrome diagnosed?
Diagnosis begins with the clinical triad and imaging of the sutures, then confirms an FGFR2 variant through targeted or panel-based sequencing. Genetic testing is interpreted alongside clinical findings by a clinician or genetic counselor.
The FGFR2 mechanism
FGFR2 is a transmembrane tyrosine kinase receptor. Ligand binding normally drives controlled signaling that regulates osteoblast proliferation and suture patency. In Apert syndrome, the causative variants sit in the linker between the second and third immunoglobulin-like extracellular domains.
These changes are gain-of-function: they increase ligand affinity and stabilize receptor activation, pushing premature osteogenic differentiation at the sutures. Wilkie and colleagues identified the adjacent Ser252Trp and Pro253Arg substitutions in all 40 unrelated cases studied and showed that Apert syndrome is allelic with Crouzon syndrome.
Genotype concentration
Few Mendelian disorders are as genotypically concentrated. Bochukova et al. reported that the two heterozygous substitutions in exon IIIa account for more than 98% of cases.
Clinical picture
Apert syndrome centers on a recognizable triad: bicoronal craniosynostosis, midface hypoplasia, and symmetric complex syndactyly. This combination necessitates lifelong, multidisciplinary intervention.
- Craniofacial: a turribrachycephalic skull, shallow orbits with proptosis, and a retruded midface that can compromise the airway.
- Limbs: symmetric bony and soft-tissue fusion of the digits, frequently involving the second through fourth fingers.
- Neurologic: variable cognitive outcomes, with hydrocephalus and raised intracranial pressure as recognized risks.
Because presentation overlaps with other FGFR-related craniosynostoses, imaging and molecular testing together sharpen the diagnosis rather than clinical inspection alone.
Epidemiology in context
Craniosynostosis as a category occurs in roughly 1 in 2,500 live births, and around eight of its 180-plus syndromic forms are linked to FGFR2 variants. Within that group, Apert syndrome is estimated at 1 in 65,000 newborns and accounts for about 4.5% of all craniosynostosis cases.
A separate analysis by Li et al. reaffirms the 1 in 65,000 figure and the tight link to FGFR2 point mutations. Reported incidence ranges up to 1 in 160,000, reflecting differences in ascertainment across populations.
Diagnostic approach
When the phenotype suggests Apert syndrome, targeted analysis of the FGFR2 exon 7 hotspots offers a high yield. If that is negative and clinical suspicion remains, broader sequencing or a craniosynostosis gene panel can capture rare deletions and insertions.
Molecular confirmation does more than label the condition. It clarifies recurrence risk for families, informs the timing of cranial vault and midface surgery, and supports anticipatory monitoring for intracranial pressure and airway compromise.
When to refer
Any newborn with the craniosynostosis-syndactyly combination warrants referral to a craniofacial team and clinical genetics. Genetic counseling should accompany testing so families understand inheritance, de novo mechanisms, and reproductive options.
If hotspot testing or a gene panel does not identify a causative variant but clinical suspicion remains, broader testing such as WES may help resolve the diagnosis. Click below to learn more about 3billion’s WES.
* This article is educational and does not provide diagnostic advice. Interpretation of any genetic result should occur with a qualified clinician or genetic counselor who can integrate findings with the full clinical picture.
References
- Wilkie AO, Slaney SF, Oldridge M, et al., Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome, 1995, DOI: 10.1038/ng0295-165, https://pubmed.ncbi.nlm.nih.gov/7719344/
- Bochukova EG, Roscioli T, Hedges DJ, et al., Rare mutations of FGFR2 causing Apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily, 2009, DOI: 10.1002/humu.20825, https://pubmed.ncbi.nlm.nih.gov/18726952/
- Li Y, Ma D, Sun Y, Meng L, Wang Y, Jiang T., Apert Syndrome With FGFR2 758 C > G Mutation: A Chinese Case Report, 2018, DOI: 10.3389/fgene.2018.00181, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966571/
Get exclusive rare disease updates
from 3billion.
Soo-jung Baek
As a marketer, I strive to empower the rare disease community by sharing meaningful insights backed by our company’s expertise.
